抗生素对小鼠菌群失调腹泻肠道菌群多样性的影响

目的探讨菌群失调腹泻抗生素造模对小鼠肠道菌群多样性的影响,为临床用药提供依据。方法运用混合抗生素建立小鼠菌群失调腹泻模型,采集肠道内容物,提取肠道微生物宏基因组,通过特定引物PCR扩增后进行扩增核糖体DNA限制性分析(Amplified rDNA Restriction Analysis,ARDRA)探讨其多样性的变化。结果正常组和模型组细菌的OTUs数为6、5,乳酸杆菌的OTUs数为6、4;模型组细菌和乳酸杆菌的多样性同正常组比较分别为59.91%、40.00%。结论抗生素造模使得肠道内的微生态平衡被破坏,肠道菌群多样性下降。     

肠道菌群调节对慢性胰腺炎腹泻的影响

目的：研究调整肠道菌群对慢性胰腺炎腹泻的影响。方法：采用治疗组与对照组相比较方法。结果;对52例慢性胰腺炎腹泻的患者在常规应用多酶片基础上加用丽珠肠乐,总有效率达93.33%。结论：慢性胰腺炎腹泻有菌群失调因素。     

运动对小鼠肠道菌群的影响

目的 利用PCR-DGGE方法比较运动小鼠和正常小鼠肠道菌群的结构和数量变化,研究运动对肠道菌群的影响。方法 从5只正常Balb/c小鼠和5只运动C57BL/6J小鼠的粪便中提取细菌基因组总DNA,用聚合酶链式反应—变性梯度凝胶电泳（PCR-DGGE）的方法获得小鼠肠道菌群分布图谱,对图谱进行相似性、多样性以及优势条带的序列分析。结果 PCR-DGGE结果图显示运动小鼠肠道菌群的多样性明显增加,优势菌群发生转变,序列分析表明变形菌门明显减少,厚壁菌门成为优势菌型。结论 运动会对小鼠肠道菌群产生影响。     

双乙酸钠对小鼠肠道菌群结构和功能的影响

肠道菌群在功能和代谢方面的研究日益成熟,但针对食品添加剂双乙酸钠对人体肠道菌群作用的研究目前仍鲜少有报道。为了探究其对肠道菌群及人体健康的潜在益处及危害,以小鼠为模型,以双乙酸钠为干预物质,干预剂量为0.3 g/(kg·d),干预1周后,收集实验小鼠和空白对照组小鼠的粪便并用菌群16S rDNA高通量测序进行肠道菌群的物种鉴定和丰度检测。对所得数据进行分析,得到小鼠肠道菌群的多样性与丰度比例等指标。结果显示,实验剂量下的双乙酸钠干预后,小鼠的肠道菌群无论是菌群种类还是丰度都有了显著改变,属水平新增447种,减少142种。根据丰度比例变化最显著的9种菌,如拟杆菌属(Bacteroides)、AKK(Akkermansia)等,并结合菌群代谢功能预测,脂肪酸合成显著上调,碳水化合物代谢、氨基酸代谢、脂代谢等明显下调,推测摄入高剂量的双乙酸钠可能有增加肥胖、过敏、慢性炎症和肠胃炎的风险。     

铁皮石斛对脾虚便秘小鼠肠道菌群多样性的影响

探讨铁皮石斛对脾虚便秘小鼠肠道菌群的影响,为铁皮石斛对脾虚便秘的疗效机制及临床组方提供依据。

选取12只SPF级昆明小鼠随机分为正常组、模型组、铁皮石斛组和枳术汤组,每组3只。造模阶段正常组灌胃无菌水,模型组和治疗组采用番泻叶水煎液灌胃7 d后,限制饮食饮水8 d,建立脾虚便秘模型。造模成功后,正常组和模型组灌胃无菌水,治疗组分别以铁皮石斛和枳术汤水煎液干预5 d。治疗结束后,收集各组小鼠盲肠内容物样本进行16S rDNA高通量测序。

脾虚便秘小鼠排便量减少,粪便细小,干燥,质硬,呈黄色。铁皮石斛和枳术汤分别治疗后,小鼠排便量增加,粪便软硬适中,呈黑褐色。测序分析发现,正常组与铁皮石斛组的共有OTU数最多,与枳术汤组的共有OTU数最少。α−多样性指数与PCA结果表明,铁皮石斛组菌属结构较其余两组更接近正常组小鼠。物种相对丰度及组成结果表明,铁皮石斛增加了脾虚便秘小鼠双歧杆菌属相对丰度,抑制了乳杆菌属、拟杆菌属相对丰度,但对菌群丰度的调节作用不及枳术汤;LEfSe分析与随机森林分析鉴定出布劳特菌属和活泼瘤胃球菌是铁皮石斛组与其他组别的差异菌群。

铁皮石斛能恢复脾虚便秘小鼠肠道菌群的多样性,可调节肠道菌群相对丰度,布劳特菌属和活泼瘤胃球菌可能是铁皮石斛干预脾虚便秘小鼠的肠道关键指示菌。

     

加替沙星对小鼠肠道菌群的影响

目的 了解加替沙星正常剂量用药和非正常剂量用药方式对小鼠肠道菌群的影响.方法 24只昆明小鼠随机分为3组,每组8只,对照组只灌胃生理盐水,另外2组分别按正常剂量和正常剂量的一半给小鼠灌胃加替沙星溶液,7 d后无菌采取小鼠粪便,观察各组小鼠粪便中双歧杆菌、类杆菌、乳酸杆菌、大肠埃希菌及肠球菌数量.结果 加替沙星灌胃7 d后,与给药前相比,肠杆菌和肠球菌药敏结果无明显变化.灌胃前后肠杆菌对CIP、LEV、GAT、AM、CRO、AMK、NOR均敏感,肠球菌对AM、LEV、VA、GAT均敏感,对NOR、CIP、CRO敏感性不同.2种用药方式可导致大肠埃希菌数量显著减少(P＜0.05),肠球菌数量稍有增加(P＞0.05).而双歧杆菌、乳酸杆菌和类杆菌数量无明显变化(P＞0.05).结论 加替沙星2种用药方式短时期对肠道菌群影响不大(肠杆菌除外),不易产生耐药性.其杀灭肠杆菌的作用远大于对厌氧菌的作用.     

微生态制剂对慢性肝衰竭患者肠道菌群的影响

目的探讨微生态调节剂双歧杆菌三联活菌对慢性肝衰竭患者肠道菌群的影响。方法根据治疗方法不同将46例慢性肝衰竭患者随机分为治疗组和对照组各23例,两组均给予慢性肝衰竭常规治疗,治疗组在上述基础上给予双歧杆菌三联活菌胶囊,210mg／粒,每次2粒,2次／d,疗程2周。观察治疗前后两组患者的肠道菌群菌落计数变化及血清总胆红素（TBiL）、凝血酶原时间（PT）变化。结果两组患者在实验前肠道菌群、TBiL、PT比较差异均无统计学意义（P〉0．05）。治疗2周后,对照组患者治疗前后肠道菌群无明显变化（P〉0．05）,TBiL、PT有所下降但不显著,治疗组患者的肠球菌、双歧杆菌、乳杆菌以及酵母样真菌的菌落数均较治疗前明显增加,TBiL、PT较前明显好转（P〈0．05）。结论口服双歧杆菌三联活菌制剂可以促进慢性肝衰竭患者肠道正常菌群的恢复及改善肝功能。     

性激素变化对小鼠肠道菌群构成的影响

肠道菌群在维持宿主免疫和消化系统功能方面发挥着重要作用,肠道菌群的多样性和丰富度是衡量宿主健康状况的重要生理指标。性激素对动物生长发育发挥重要作用,但其对肠道菌群构成影响的相关实验研究相对较少。本研究以模式生物小鼠（Mus musculus）为对象,探究性激素的变化对小鼠肠道菌群构成的影响。采用外科手术方式建立小鼠去势模型,通过16S r RNA高通量测序技术,研究性激素对小鼠肠道菌群构成的影响。研究结果表明,雌性小鼠和雄性小鼠去势后,性激素水平显著下降。肠道菌群在门水平上,正常小鼠和去势小鼠肠道细菌群落均由拟杆菌门（Bacteroidetes）、厚壁菌门（Firmicutes）、变形菌门（Proteobacteria）、埃普西隆杆菌门（Epsilonbacteraeota）、髌骨细菌门（Patescibacteria）、放线菌门（Actinobacteria）、软壁菌门（Tenericutes）、脱铁杆菌门（Deferribacteres）、酸杆菌门（Acidobacteria）和蓝藻细菌门（Cyanobacteria）组成,主要菌群为厚壁菌门和拟杆菌门物种,两门占物种相对丰度百分比...     

慢性肝病与肠道菌群的研究进展

肝脏与肠道微生态可谓息息相关,互为影响。慢性肝病患者均存在不同程度的菌群失调,而菌群失调与血内毒素水平升高相关,且可诱发肝性脑病、二重感染的发生。肠道菌群失调促进了慢性肝病并发症的发生、发展,增加了患者的死亡率,且菌群失调与肝功能损害程度成正比。微生态制剂可通过恢复肠道菌群平衡,维持肠道屏障的完整性,抑制产生内毒素的G-数量,减少肠氨的产生,辅助治疗慢性肝病。     

Leukemic transformation of hematopoietic cells in mice internally exposed to depleted uranium

Depleted uranium (DU) is a dense heavy metal used in military applications. During military conflicts, US military personnel have been wounded by DU shrapnel. The health effects of embedded DU are unknown. Published data from our laboratory demonstrated that DU exposure in vitro can transform immortalized human osteoblast cells (HOS) to the tumorigenic phenotype. Results from our laboratory have also shown that DU is genotoxic and mutagenic in cultured human cells. Internalized DU could be a carcinogenic risk and concurrent alpha particle and heavy metal toxic effects complicate this potential risk. Anecdotal reports have suggested that DU can cause leukemia. To better assess this risk, we have developed an in vivo leukemogenesis model. This model involves using murine hematopoietic cells (FDC-P1) that are dependent on stimulation by granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin 3 (IL-3) and injected into mice to produce myeloid leukemia. Although immortalized, these cells are not tumorigenic on subcutaneous inoculation in mice. Intravenous injection of FDC-P1 cells into DU-implanted DBA/2 mice was followed by the development of leukemias in 76% of all mice implanted with DU pellets. In contrast, only 12% of control mice developed leukemia. Karyotypic analysis confirmed that the leukemias originated from FDC-P1 cells. The growth properties of leukemic cells from bone marrow, spleen, and lymph node were assessed and indicate that the FDC-P1 cells had become transformed in vivo. The kidney, spleen, bone marrow, muscle, and urine showed significant elevations in tissue uranium levels prior to induction of leukemia. These results demonstrated that a DU altered in vivo environment may be involved in the pathogenesis of DU induced leukemia in an animal model.     

Toxicity of depleted uranium complexes is independent of p53 activity

The p53 tumor suppressor protein is one of the key checkpoints in cellular response to a variety of stress mechanisms, including exposure to various toxic metal complexes. Previous studies have demonstrated that arsenic and chromium complexes are able to activate p53, but there is a dearth of data investigating whether uranium complexes exhibit similar effects. The use of depleted uranium (DU) has increased in recent years, raising concern about DU's potential carcinogenic effects. Previous studies have shown that uranyl acetate and uranyl nitrate are capable of inducing DNA strand breaks and potentially of inducing oxidative stress through free radical generation, two potential mechanisms for activation of p53. Based on these studies, we hypothesized that either uranyl acetate or uranyl nitrate could act as an activator of p53. We tested this hypothesis using a combination of cytotoxicity assays, p53 activity assays, western blotting and flow cytometry. All of our results demonstrate that there is not a p53-mediated response to either uranyl acetate or uranyl nitrate, demonstrating that any cellular response to uranium exposure likely occurs in a p53-independent fashion under the conditions studied.     

Brain accumulation of depleted uranium in rats following 3- or 6-month treatment with implanted depleted uranium pellets

Depleted uranium (DU) is used to reinforce armor shielding and increase penetrability of military munitions. Although the data are conflicting, DU has been invoked as a potential etiological factor in Gulf War syndrome. We examined regional brain DU accumulation following surgical implantation of metal pellets in male Sprague-Dawley rats for 3 or 6 mo. Prior to surgery, rats were randomly divided into five groups: Nonsurgical control (NS Control); 0 DU pellets/20 tantalum (Ta) pellets (Sham); 4 DU pellets/16 Ta pellets (Low); 10 DU pellets/10 Ta pellets (Medium); 20 DU pellets/0 Ta pellets (High). Rats were weighed weekly as a measure of general health, with no statistically significant differences observed among groups in either cohort. At the conclusion of the respective studies, animals were perfused with phosphate-buffered saline, pH 7.4, to prevent contamination of brain tissue with DU from blood. Brains were removed and dissected into six regions: cerebellum, brainstem (pons and medulla), midbrain, hippocampus, striatum, and cortex. The uranium content was measured in digested samples as its ²³⁸U isotope by high-resolution inductively coupled plasma-mass spectrometry. After 3 mo postimplantation, DU significantly accumulated in all brain regions except the hippocampus in animals receiving the highest dose of DU (p<0.05). By 6 mo, however, significant accumulation was measured only in the cortex, midbrain, and cerebellum (p<0.01). Our data suggest that DU implanted in peripheral tissues can preferentially accumulate in specific brain regions.     

Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice

Although pancreatic enzyme replacement therapy (PERT) is effective in the alleviation of pancreatic exocrine insufficiency (PEI)-related symptoms in patients with chronic pancreatitis, its mechanism of action is poorly understood. Recent studies suggest that the intestinal microbiota is associated with the pathogenesis of chronic pancreatitis. Therefore, we hypothesized that PERT exerts its effect by modifying the intestinal microbiota in addition to its presumed role in promoting fat and protein absorption. To explore the mechanism of action of PERT, we analyzed the intestinal microbiotas of two groups of mice treated with either pancrelipase or tap water by using 16S rRNA amplicon sequencing. The results revealed that the bacterial compositions of the pancrelipase-treated mice were significantly different from those of the control samples. Akkermansia muciniphila, a key beneficial bacterium in the intestinal tract, showed a higher relative abundance in the pancrelipase-treated samples than in the control samples. Lactobacillus reuteri, a widely used probiotic bacterium known to relieve intestinal inflammation, also showed a higher relative abundance in the pancrelipase-treated samples. These results suggested that PERT induces the colonization of beneficial bacteria, thereby contributing to the attenuation of PEI-associated symptoms in addition to improvement of the nutritional state.     

肠道微生物群落与炎症性肠病关系研究进展

目的炎症性肠病（IBD）包括克罗恩病（CD）和溃疡性结肠炎（UC）,以持续性肠道非特异性炎症为特征,通常反复发作、迁延不愈,临床上仍无特效性的治疗手段。IBD确切的发病机制尚不清楚,涉及免疫、环境及遗传等因素,这些因素共同诱导肠道炎症、黏膜损伤和修复。肠道微生物群落及其代谢产物、宿主基因易感性及肠道黏膜免疫三方面共同参与了IBD的发病机制。本文从消化道微生态角度出发,对目前IBD相关的肠道微生物群落研究现状、宿主-微生物间免疫应答及益生菌治疗等内容进行探讨。     

Intestinal microbiota in human health and disease: the impact of probiotics

The complex communities of microorganisms that colonise the human gastrointestinal tract play an important role in human health. The development of culture-independent molecular techniques has provided new insights in the composition and diversity of the intestinal microbiota. Here, we summarise the present state of the art on the intestinal microbiota with specific attention for the application of high-throughput functional microbiomic approaches to determine the contribution of the intestinal microbiota to human health. Moreover, we review the association between dysbiosis of the microbiota and both intestinal and extra-intestinal diseases. Finally, we discuss the potential of probiotic microorganism to modulate the intestinal microbiota and thereby contribute to health and well-being. The effects of probiotic consumption on the intestinal microbiota are addressed, as well as the development of tailor-made probiotics designed for specific aberrations that are associated with microbial dysbiosis.     

肠道微生物多样性与能量代谢调控及肥胖关系的研究进展

肠道微生物与宿主之间相互选择,构成了一个相对稳定的超有机体。宿主基因型和遗传关系影响肠道微生物的生态学特征,而肠道微生物发酵肠道内多糖,为宿主提供可吸收利用的养分,增强肠道对养分吸收的能力。同时,肠道微生物还影响一些转录因子的活性,调控宿主基因的表达,增强宿主甘油三酯的合成和脂肪沉积,减少脂肪酸氧化分解,调控宿主能量代谢。     

口炎清颗粒对小鼠肠道菌群失衡的调节作用

目的探讨口炎清颗粒对肠道菌群失衡的调节作用。方法小鼠随机分为6组：正常对照组、重度失调组、自然恢复组、口炎清低剂量组、口炎清高剂量组和大豆低聚糖对照组。正常对照组小鼠灌服蒸馏水,其他组以头孢曲松钠终浓度为8 g/（kg.d）的剂量,连续灌胃8 d,建立小鼠菌群失衡模型,自然恢复组在失衡模型建立后不使用任何药物,自然恢复7 d;口炎清低剂量组、高剂量组、大豆低聚糖对照组分别灌服相应剂量的药物7 d,观察各组小鼠盲肠指数和肠道内双歧杆菌、类杆菌、韦荣球菌、乳酸杆菌、消化球菌、优杆菌、葡萄球菌、肠球菌、大肠埃希菌、链球菌和酵母菌11种菌群变化。结果与菌群失衡组比较,口炎清组与大豆低聚糖组盲肠指数均显著下降（P〈0.05）,呈恢复趋势。自然恢复组肠道菌群种类和数量变化不明显,口炎清组厌氧菌重新出现,尤其是低剂量组双歧杆菌、优杆菌和类杆菌的出现预示着肠道菌群正在逐渐恢复正常。结论一定浓度的口炎清可以明显促进菌群失衡小鼠盲肠大小的恢复,对小鼠肠道菌群有调节作用,具有类似大豆低聚糖的益生元功效。